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Objectives. We aimed to investigate the association between the expression of phosphorylated AktThr308 (p-AktThr308) in oral
squamous cell carcinoma (OSCC) tissues and clinicopathological parameters of OSCC patients and to verify the validity of
p-AktThr308 as a prognostic biomarker.
Study design. One hundred and ninety-one patients with OSCC were recruited for the study. We tested the expression of
p-AktThr308 by immunohistochemistry (IHC) with tissue microarray (TMA) and analyzed with digital pathology analysis
software. The clinicopathological parameters of all patients were collected from follow-up.
Results. P-AktThr308 was detected in 95.2% of OSCC patients. The expression of p-AktThr308 was significantly correlated with
local recurrence and five-year survival rate. High expression of p-AktThr308 in OSCC was associated with poor prognosis.
Conclusion. P-AktThr308 might be a candidate biomarker for the prediction of OSCC prognosis. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2013;116:591-597)Oral squamous cell carcinoma (OSCC) is one of the
most common malignancies, affecting about 275,000
individuals annually worldwide.1 Recently, an increase
in OSCC incidence has been reported, probably due to
greater general life-expectancy and increasing alcohol
and tobacco consumption.2 Additionally, it has also
been reported that human papillomavirus (HPV)
infection might be involved in the pathogenesis of
OSCC.3 OSCC has a tendency for loco-regional
recurrence, second primary tumors and poor survival.4
In clinical practice, the clinical tumor-node-metastasis
(TNM) classiﬁcation system has been widely used for
the prediction of OSCC prognosis, however, the
predictive effect is poor, even for patients in the early
stage (I and II) groups. Therefore, it is important to1These authors contributed equally to this work.
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The phosphorylated Akt (p-Akt) is an activated form
of Akt that plays a central role in a variety of human
cancers. Akt, also known as protein kinase B (PKB), is
a 52 kDa serine/threonine kinase with three isoforms:
Akt-1, Akt-2, and Akt-3.5 All isoforms of Akt share a
high percentage of amino acid identity. Each isoform
is composed of three functionally distinct regions: an
N-terminal pleckstrin homology (PH) domain involved
in lipid binding, a kinase domain and a C-terminal ‘tail.’
Akt activation is initiated by binding of its PH domain
with 3-phosphoinositides generated by the phosphoino-
sitides 3-kinase (PI3 K).5 After that, Akt will be trans-
located to the plasma membrane. However, Akt is not
fully activated until it is further phosphorylated by 3-
phosphoinositide-dependent kinase1 (PDK1) at Thr-308
and by PDK2 at Ser-473.6 The activation of Akt is
negatively regulated by phosphatase and tensin homolog
deleted on chromosome ten (PTEN), a tumor suppressor
gene deleted in multiple human cancers.7 Akt activation
has been implicated in a variety of biological responses
including nutrient metabolism, cell growth, apoptosis,
and survival. Active Akt promotes cell survival by
phosphorylating and inactivating the pro-apoptotic B-cellStatement of Clinical Relevance
Increased p-Akt expression in OSCC may indicate
poor clinical outcome of OSCC, therefore, it can
have signiﬁcance in treatment planning.
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associated death promoter (BAD), as well as affecting
the transcriptional response to apoptotic stimuli and the
activity of the p53 family.8 It has also been reported that
Akt maintains cell size and survival by increasing
mammalian target of rapamycin (mTOR)-dependent
nutrient uptake.9 Moreover, p-Akt activates mTOR
through direct phosphorylation and inhibition of the
tuberous sclerosis 2 (TSC2) tumor suppressor.10 Alter-
ation of Akt activity has been demonstrated in several
human cancers including OSCC.11-13 Akt activation is
associated with enhanced tumor cell invasion of pan-
creatic carcinoma cells and OSCC cells.14,15 Further-
more, it has been linked to aggressive clinical behavior
and loss of histological features of epithelial differenti-
ation in ovarian carcinomas.16 In general, activation of
p-Akt regulates cell survival, proliferation, and invasion.
Hence, p-Akt might be a good predictor of tumor
aggressiveness.
The prognostic value of p-Akt in cancers has been
reported in several previous studies, however, the sample
size of these studies was relatively small.12,13,17,18 In
order to get a better understanding of the correlation
between p-Akt expression and OSCC, we examined the
expression of p-Akt in OSCC patients in a larger sample
size by tissue microarray (TMA). Our results showed
that elevated p-AktThr308 expression was a predictor for
poor clinical outcome of OSCC. Thus, it might be
a potential biomarker for the prediction of OSCC prog-
nosis and a possible target for OSCC treatment.
MATERIALS AND METHODS
Subjects and follow-up
This study was conducted in West China Hospital of
Stomatology, Sichuan University (Chengdu, China)
from 2002 to 2011. It was approved by the Committee
for the Use of Human Subjects in Research, Sichuan
University. Written informed consent was obtained
from all subjects. A total of 191 patients with OSCC
were recruited for the study, the diagnosis were all
performed by senior specialists in oral surgery and oral
pathology with more than 10 years’ experience. Patients
were treated surgically and all surgical margins were
clear of tumor cells (clear > 5 mm). None of the
patients received any preoperative chemotherapy or
postoperative adjuvant radiotherapy, but some patients
received postoperative chemotherapy.
All patients were examined routinely every 3 months
during the ﬁrst year of follow-up, then every 6 months in
the following 4 years and once a year thereafter. Clinical
data of patients were censored at the date of last in-
person visit or April 30th, 2012, irrespective of whether
the patient was alive or not. Survival time was deﬁned as
the time from the study entry to death or the last follow-
up visit. Essential information of patients was collected,including sex, age, smoking, and alcohol consumption,
systemic diseases (including hypertension and diabetes),
cell differentiation, tumor stage (small, T1/T2; large, T3/
T4), lymph node metastasis, clinical TNM stage (early
stage, I/II; late stage, III/IV), chemotherapy after surgical
procedure, recurrence, survival time and ﬁve-year
survival.TMA design and IHC assay
A Tissue Arrayer device (Beecher Instrument, MD, USA)
was used to construct TMA with cores of OSCC tissues
from the 191 patients. All cases were histologically
reviewed and the areas representative of histological
subtype were marked in the corresponding parafﬁn
blocks. In each case, two selected cylinders (1.5 mm in
largest diameter) were removed from two different tumor
loci of the same block and subsequently brought into one
empty ‘recipient’ parafﬁn block. Thus, four different
TMA blocks were constructed from formalin-ﬁxed,
parafﬁn-embedded blocks of 191 OSCCs.
TMA blocks were sectioned at a thickness of 4 mm
and heated to 55 C, dehydrated in xylene and graded
alcohols. Antigen retrieval was performed with 0.01 M
citrate buffer at pH 6.0 at 95 C. Before staining,
endogenous peroxidase was blocked with 3% hydrogen
peroxide solution. Immunohistochemical staining was
performed on the TMA slides using primary antibody
against p-Akt (Rabbit polyclonal pan-AKT (phospho
T308) antibody, abcam, USA). TMA slides were
incubated with primary antibody diluted in 50 mM
TriseHCl (pH 7.6), 150 mM NaCl, and 0.1% Tween 20
at 4 C overnight, followed by incubations with the
ChemMate EnVision/HRP, Rabbit/Mouse (ENV)
reagent of Envision Detection Kit (Dako Corporation,
Carpinteria, CA, USA) for 30 min. The reaction was
visualized with the ChemMate DAB þ chromogen of
Envision Detection Kit. Slides were counterstained with
Harris hematoxylin, dehydrated and mounted. Sections
of formalin-ﬁxed, parafﬁn-embedded human breast
carcinoma samples were used as a positive control for
p-Akt, and the negative control was run without addi-
tion of the primary antibody.Semi-quantitation of IHC results
The staining images of TMA were acquired using Aperio
Scanscope Virtual scanning microscopic imaging system
(Aporio Scanscope FL þ GL; Aperio, Vista, CA, USA).
Saturation and intensity of each tissue core were
measured by Positive Pixel Count Algorithm, TMALab,
Genie software (Aperio), which determined the average
intensity of pixels and the percentage of cells stained
within the tissue region of interest. The evaluation was
performed three times by three independent investiga-
tors. For quality control, 50 tissue cores were randomly
Table I. Clinicopathological parameters and charac-






1 (low), N (%)
Subgroup
2 (high), N (%)
Sex
Male 134 (70.2) 63 (64.3) 71 (76.3)
Female 57 (29.8) 35 (35.7) 22 (23.7)
Age (year)
<60 90 (47.1) 44 (44.9) 46 (49.5)
60 101 (52.9) 54 (55.1) 47 (50.5)
Smoking
Yes 99 (51.8) 41 (41.8)* 58 (62.4)*
No 92 (48.2) 57 (58.2)* 35 (37.6)*
Drinking
Yes 99 (51.8) 43 (43.9)* 56 (60.2)*
No 92 (48.2) 55 (56.1)* 37 (39.8)*
Systemic diseases
Yes 62 (32.5) 32 (32.7) 30 (32.3)
No 129 (67.5) 66 (67.3) 63 (67.7)
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tion and intensity were analyzed by two pathologists
using uniform criteria. These tissue cores were eval-
uated over 8 visual ﬁelds at a power of 400 under
a light microscope (Olympus Optical, Tokyo, Japan).
No signiﬁcant differences were found between these
two methods.
Staining of p-AktThr308 was scored as average inten-
sity of all pixels (Iavg, Iavg ¼ (Iwp þ Ip þ Isp)/
(Nwp þ Np þ Nsp); Iwp, sum of intensity values for all
weak-positive pixels; Ip, sum of intensity values for
all positive pixels; Isp, sum of intensity values for all
strong-positive pixels; Nwp, number of weak-positive
pixels; Np, number of positive pixels; Nsp, number of
strong-positive pixels). The staining of each tissue core
was scored with 0 or 1 or 2 or 3 based on the Iavg
(0 ¼ Iavg > 196, 1 ¼ 182  Iavg  196,
2 ¼ 172  Iavg < 182, 3 ¼ Iavg < 172).Cell differentiation
Well 127 (66.5) 71 (72.4) 56 (60.2)
Moderate/poor 64 (33.5) 27 (27.6) 37 (39.8)
Tumor stage
Small (T1/T2) 106 (55.5) 58 (59.2) 48 (51.6)
Large (T3/T4) 85 (44.5) 40 (40.8) 45 (48.4)
Lymph node metastasis
Non-metastatic 128 (67.0) 73 (74.5)* 55 (59.1)*
Metastatic 63 (33.0) 25 (25.5)* 38 (40.9)*
Clinical TNM stage
Early stage (I/II) 80 (41.9) 49 (50.0)* 31 (33.3)*
Late stage (III/IV) 111 (58.1) 49 (50.0)* 62 (66.7)*
Chemotherapy after surgical procedure
Yes 100 (52.4) 52 (53.1) 48 (51.6)
No 91 (47.6) 46 (46.9) 45 (48.4)
Recurrence
Yes 43 (22.5) 13 (13.3)* 30 (32.3)*
No 148 (77.5) 85 (86.7)* 63 (67.7)*
Survival time (month)
Mean  SD 37.2  25.2 42.8  26.4* 31.5  22.6*
Five-year survival
Yes 61 (31.9) 49 (50.0)* 12 (12.9)*
No 130 (68.1) 49 (50.0)* 81 (87.1)*
*P < .05, unpaired student’s t test was used for hypothesis testing of
the relationship between survival time and p-AktThr308. Chi-square
test was used for hypothesis testing of the relationship between the
other variables and p-AktThr308.Statistical analysis
Continuous variables were presented as means standard
deviations (SD). Categorical variables were presented as
frequencies and percentages. Associations between the
clinicopathological characteristics of the patients and
p-AktThr308 expression levels were analyzed by chi-square
test or unpaired Student’s t test. Univariate logistic
regressions were used to evaluate the predictive effect of
each factor for OSCC recurrence. All potential factors
inﬂuencing the probability of recurrence were analyzed,
including sex, age (<60 or 60), smoking, drinking,
systemic diseases (including hypertension and diabetes),
cell differentiation, tumor stage (small, T1/T2; large, T3/
T4), lymph node metastasis, clinical TNM stage (early
stage, I/II; late stage, III/IV), chemotherapy after surgical
procedure and p-AktThr308 expression level. Furthermore,
some factors (P < .05) in univariate logistic regression
were included in the multivariable step-wise logistic
regression model. Survival curves were determined by the
KaplaneMeier method, and the differences were
compared on the basis of variables’ category with the use
of the log-rank test. To determine the hazard ratio,
univariate Cox proportional-hazards model was used to
assess the contribution of the following factors: sex, age
(<60 or 60), smoking, drinking, systemic diseases
(including hypertension and diabetes), cell differentiation,
tumor stage (small, T1/T2; large, T3/T4), lymph node
metastasis, clinical TNM stage (early stage, I/II; late stage,
III/IV), chemotherapy after surgical procedure and p-
AktThr308 expression level. Multivariate step-wise Cox
proportional-hazards model was used to evaluate the
overall survival with inclusion of all signiﬁcant variables
(P < .05) identiﬁed by the univariate analysis. To deter-
mine discrimination, the sensitivity and speciﬁcity of the
given data were identiﬁed as well.RESULTS
Clinicopathological parameters of 191 patients
with OSCC
A total of 191 OSCC patients were recruited in this
study, only 5 patients dropped out for private
reasons. Therefore, the discontinuation rate, 2.6%,
was quite low, thus having no inﬂuence on the
interpretation or conclusions. This cohort of OSCC
patients included 134 (70.2%) male and 57 (29.8%)
female, with a median age of 60 years. The clini-
copathological parameters of all the samples can
be found in Table I.
Fig. 1. Immunohistochemical staining of p-AktThr308 in OSCC. Positive staining in nucleus and cytoplasm (A and B) scoring of
0 (original magniﬁcation, 10, 200); (C and D) scoring of 1 (original magniﬁcation, 10, 200); (E and F) scoring of 2
(original magniﬁcation, 10, 200); (G and H) scoring of 3 (original magniﬁcation, 10, 200).
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clinicopathological parameters
The expression of p-AktThr308 was scored based on the
Iavg (Figure 1). The patients with score 0 (4.7%) and 1
(46.6%) were classiﬁed into subgroup 1(low expression
of p-AktThr308), the patients with score 2 (39.8%) and 3
(8.9%) were classiﬁed into subgroup 2 (high expression
of p-AktThr308). The two groups were well matched to
sex and age (Table I).
The increased expression of p-AktThr308 in OSCC
was signiﬁcantly associated with smoking (P ¼ .005),
drinking (P ¼ .024), increased frequencies of lymph
node metastasis (P ¼ .024), high clinical TNM stage
(P ¼ .020), recurrence (P ¼ .002), and decreased
survival time (P < .001) and ﬁve-year survival rate
(P < .001).
Multivariable logistic regression analysis on
influencing factors for local recurrence
The potential indexes inﬂuencing the probability of
recurrence included sex, age (<60 or 60), smoking,
drinking, systemic diseases (including hypertension
and diabetes), cell differentiation, tumor stage (small,
T1/T2; large, T3/T4), lymph node metastasis, clinical
TNM stage (early stage, I/II; late stage, III/IV),
chemotherapy after surgical procedure and p-AktThr308
expression level. All these factors were included in
univariate logistic regression analysis (Table II). To
get a more precise combined analysis of all factors
and to control for confounding factors more effec-
tively, four factors (P < .05) from the univariate
logistic regression, including cell differentiation,lymph node metastasis, clinical TNM stage (early
stage, I/II; late stage, III/IV) and p-AktThr308 expres-
sion, were analyzed in the multivariable step-wise
logistic regression model. The result showed that
clinical TNM stage (P ¼ .007, OR ¼ 3.068, 95% CI:
1.354-6.948) and p-AktThr308 expression level
(P ¼ .008, OR ¼ 2.740, 95% CI: 1.302-5.767) could
signiﬁcantly inﬂuence the probability of recurrence
(Table III).
Survival analysis
The KaplaneMeier survival analysis was applied to
estimate cancer-speciﬁc survival rates. The results
showed that the cumulative survival rate of patients with
high p-AktThr308 expression was signiﬁcantly lower than
those with low p-AktThr308 expression (P < .001).
Additionally, we performed subgroup analysis concern-
ing cell differentiation, tumor stage, lymph node metas-
tasis, clinical TNM stage, and recurrence. In all the
subgroups, high p-AktThr308 expression was signiﬁcantly
associated with poor survival (data not shown). Univar-
iate Cox proportional hazards survival analysis showed
that the survival of patients was associated with several
prognostic factors (Table IV). Poor prognosis was
signiﬁcantly associated with moderate or poor cell
differentiation (P ¼ .042), high tumor stage (P ¼ .013),
positive lymph node metastasis (P ¼ .001), high clinical
TNM stage (P < .001), recurrence (P ¼ .030) and high
p-AktThr308 expression level (P < .001). Multivariate
step-wise Cox proportional hazards survival analysis
conﬁrmed the prognostic value of high clinical TNM
stage (P < .001, OR ¼ 1.947, 95% CI: 1.341-2.828) and
Table II. Univariate logistic regression analysis of inﬂuencing factors for recurrence in 191 patients with OSCC
Variables b SE Wald c2 P value OR 95% CI
Sex (M/F) 0.024 0.378 0.004 .949 1.024 0.489-2.147
Age (<60/60) 0.032 0.347 0.008 .928 1.032 0.523-2.038
Smoking (yes/no) 0.035 0.347 0.010 .920 0.966 0.490-1.906
Drinking (yes/no) 0.035 0.347 0.010 .920 0.966 0.490-1.906
Systemic diseases (yes/no) 0.133 0.375 0.126 .723 0.876 0.420-1.827
Cell differentiation (well/moderate, poor) 0.846 0.355 5.690 .017 2.331 1.163-4.672
Tumor stage (small/large) 0.346 0.347 0.992 .319 1.413 0.715-2.793
Lymph node metastasis (non-metastatic/metastatic) 0.753 0.355 4.491 .034 2.123 1.058-4.261
Clinical TNM stage (early stage/late stage) 1.248 0.409 9.293 .002 3.483 1.561-7.771
Chemotherapy after surgical procedure (yes/no) 0.550 0.356 2.392 .122 1.734 0.863-3.482
p-AktThr308 expression (low/high) 1.136 0.371 9.355 .002 3.114 1.504-6.447
OR, odds ratio; CI, conﬁdence interval; Small, T1/T2; Large, T3/T4; Early stage, I/II; Late stage, III/IV.
Table III. Multivariate logistic regression analysis of inﬂuencing factors of recurrence in 191 patients with OSCC
Variables b SE Wald c2 P value OR 95% CI
Clinical TNM stage (early stage/late stage) 1.121 0.417 7.221 .007 3.068 1.354-6.948
p-AktThr308 expression (low/high) 1.008 0.380 7.049 .008 2.740 1.302-5.767
OR, odds ratio; CI, conﬁdence interval; Nagelkerke R Square, 0.438; Early stage, I/II; Late stage, III/IV.
Table IV. Univariate analysis of survival in 191 patients with OSCC according to the Cox proportional-hazards
model
Variables b SE Wald c2 P value OR 95% CI
Sex (M/F) 0.128 0.194 0.432 .511 0.880 0.601-1.288
Age (<60/60) 0.109 0.176 0.385 .535 0.897 0.636-1.265
Smoking (yes/no) 0.051 0.176 0.082 .774 1.052 0.745-1.485
Drinking (yes/no) 0.051 0.176 0.083 .773 0.951 0.674-1.341
Systemic diseases (yes/no) 0.341 0.195 3.070 .080 0.711 0.486-1.041
Cell differentiation (well/moderate, poor) 0.371 0.182 4.151 .042 1.449 1.014-2.070
Tumor stage (small/large) 0.435 0.176 6.123 .013 1.544 1.095-2.179
Lymph node metastasis (non-metastatic/metastatic) 0.610 0.180 11.450 .001 1.841 1.293-2.622
Clinical TNM stage (early stage/late stage) 0.764 0.189 16.411 .000 2.147 1.483-3.107
Chemotherapy after surgical procedure (yes/no) 0.097 0.176 0.308 .579 0.907 0.643-1.280
Recurrence (yes/no) 0.429 0.197 4.733 .030 1.535 1.043-2.259
p-AktThr308 expression (low/high) 0.799 0.183 19.116 .000 2.223 1.554-3.181
OR, odds ratio; CI, conﬁdence interval; Small, T1/T2; Large, T3/T4; Early stage, I/II; Late stage, III/IV.
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OR ¼ 2.032, 95% CI: 1.415-2.917) (Table V).
Receiver operating characteristic (ROC) curve
analysis
To determine discrimination, the ROC curve was used
to identify the sensitivity and speciﬁcity of the given
data. In our study, The ROC area for p-AktThr308 alone
was 0.71 and that for clinical TNM stage alone was
0.67. An area under the ROC curve of 0.7-0.9 is
considered excellent discrimination, whereas a ROC
value of 0.5 indicates no discrimination.19 Thus, the
result indicated that p-AktThr308 showed excellent
discrimination and might be a better predictor of OSCC
clinical outcome compared to clinical TNM stage
(Figure 2).DISCUSSION
P-Akt is a protein, which is involved in the regulation of
several aspects of cell function. It has been proven that
p-Akt is overexpressed in OSCC.13,15,20 The down-
stream target of p-Akt, phosphorylated mTOR, appears
to be a reliable biomarker in human head and neck
cancer.21 Additionally, Forkhead box O3a (FOXO3a)
activation, which is suppressed by p-Akt, has also been
reported to be a potent therapeutic strategy for OSCC.22
Both Thr308 and Ser473 are the main phosphorylation
sites of Akt, and are crucial for the formation of p-Akt. In
vivo, phosphorylation of Thr308 is not dependent on
phosphorylation of Ser473 or vice versa.23 However, the
regulatory mechanisms and physiological importance of
each phosphorylation site remain unclear. P-AktSer473 is
dispensable for Akt downstream targets, TSC2 and
Table V. Multivariate analysis of survival of 191 patients with OSCC according to the Cox proportional-hazards
model
Variables b SE Wald c2 P value OR 95% CI
Clinical TNM stage (early stage/late stage) 0.666 0.190 12.245 .000 1.947 1.341-2.828
p-AktThr308 expression (low/high) 0.709 0.184 14.772 .000 2.032 1.415-2.917
OR, odds ratio; CI, conﬁdence interval; Early stage, I/II; Late stage, III/IV.
Fig. 2. ROC curves of p-AktThr308 and clinical TNM stage.
The ROC area for p-AktThr308 alone was 0.71 and for clinical
TNM stage alone was 0.67, indicating excellent dis-
crimination of p-Akt compared with clinical TNM stage.
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rapamycin complex 1 (TORC1) effectors, S6 ribosomal
kinase (S6 K) and 4E-binding protein 1 (4E-BP1).24
But these targets have been implicated in mediating
a variety of biological responses in human cancer. P-
AktThr308 may play an important role in the conversion
of a potentially malignant oral lesion to carcinoma.25 It
has been reported that p-AktThr308 predicts poor prog-
nosis in acute myeloid leukemia.26 Although a small
sample study (84 cases) has shown that p-AktSer473
predicts poor clinical outcome in OSCC through tradi-
tional IHC, the correlation between p-AktThr308 and
prognosis in OSCC has not been reported.13
In this study, TMAs were constructed from
191 OSCC tissues, and detailed clinicopathological
parameters were collected from regular follow-up.
P-AktThr308 expression was detected in 95.2% of
OSCCs. Our results showed that p-AktThr308 expression
was signiﬁcantly associated with smoking and alcohol
consumption, lymph node metastasis, TNM stage,
recurrence, survival times, and ﬁve-year survival rate.
This was different from a previous study, in which p-
AktSer473 was analyzed and was only associated with
lymph node metastasis and TNM stage.13Local recurrence is one of the main causes of
treatment failure of OSCC, and contributes signiﬁ-
cantly to the relatively low survival rates of this
neoplasm. The recurrence rate of OSCC varies from
18% to 76% in patients undergoing standard treat-
ment.27,28 Our study showed that the elevated
p-AktThr308 expression had a signiﬁcant association
with the probability of recurrence in OSCC. Further-
more, survival analysis showed that increased
p-AktThr308 expression was signiﬁcantly associated
with lower survival. Various biological activities
of p-Akt, such as enhancement of proliferation,
invasiveness, and anti-apoptosis, may cause micro-
invasiveness at the resected margin and promote
the invasion and recurrence of OSCC. Thus, high
p-AktThr308 expression in an OSCC patient may
predict high probability of recurrence and shorter
survival time. Multivariate logistic regression analysis
and survival analysis showed that p-AktThr308 and
clinical TNM stage were independent prognostic
indicators. TNM stage is a conventional, useful index
for OSCC prognosis in clinical practice. As noted
above, p-AktThr308 showed potential as an excellent
predictive biomarker for OSCC prognosis. Further-
more, when the sensitivity and speciﬁcity were
assessed, p-AktThr308 showed good discrimination as
a predictor for OSCC clinical outcome. Thus,
p-AktThr308 may be a potential biomarker for OSCC
classiﬁcation. If p-AktThr308 could be used together
with clinical TNM stage, it may help identify indi-
viduals with a poor prognosis.
In conclusion, increased p-AktThr308 expression was
an excellent predictor of poor clinical outcome in
OSCC. Therefore, it could represent a potential
biomarker for the prediction of prognosis, and poten-
tially be a target for OSCC treatment.
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